Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series
Thyroid2012Vol. 23(1), pp. 50–57
Citations Over TimeTop 10% of 2012 papers
Raffaele Ciampi, Caterina Mian, Laura Fugazzola, Barbara Cosci, Cristina Romei, Susi Barollo, Valentina Cirello, Valeria Bottici, Giulia Marconcini, Pelizzo Maria Rosa, Maria Grazia Borrello, Fulvio Basolo, Clara Ugolini, Gabriele Materazzi, Aldo Pinchera, Rossella Elisei
Abstract
The prevalence of RAS mutations in our MTC series was relatively low and consistent with the meta-analysis data. Only somatic RAS mutations were found and only in RET-negative sMTC. Likewise, MTCs that harbor a RAS mutation identify a subgroup of tumors with less aggressive behavior. To our knowledge, this is the largest series of MTCs studied for the presence of mutations in RAS genes and the first meta-analysis on this specific topic.
Related Papers
- → Protein Kinase Inhibitor Therapy in Advanced Thyroid Cancer: Ethical Challenges and Potential Solutions(2014)8 cited
- → Medullary Thyroid Cancer(2000)3 cited
- → Medullary and non-medullary thyroid cancer in a family(2004)
- → Targeted and Salvage Therapies Benefit Patients With Thyroid Cancer(2015)
- → Medullary Cancer(2007)